Vasundhara Rasayans Ltd
Incorporated in 1987, Vasundhara Rasayans Ltd is a manufacturer and exporter of Antacids[1]
- Market Cap ₹ 35.9 Cr.
- Current Price ₹ 113
- High / Low ₹ 267 / 101
- Stock P/E 9.46
- Book Value ₹ 123
- Dividend Yield 1.77 %
- ROCE 16.6 %
- ROE 12.6 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.92 times its book value
- Debtor days have improved from 61.2 to 44.6 days.
Cons
- The company has delivered a poor sales growth of 9.93% over past five years.
- Earnings include an other income of Rs.3.04 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.83 | 18.40 | 15.27 | 15.41 | 16.58 | 19.71 | 21.17 | 22.68 | 26.70 | 37.88 | 36.96 | 33.99 | 31.59 | |
| 17.27 | 16.80 | 13.97 | 13.76 | 14.78 | 18.55 | 18.33 | 19.57 | 24.49 | 32.32 | 30.53 | 29.88 | 28.62 | |
| Operating Profit | 3.56 | 1.60 | 1.30 | 1.65 | 1.80 | 1.16 | 2.84 | 3.11 | 2.21 | 5.56 | 6.43 | 4.11 | 2.97 |
| OPM % | 17.09% | 8.70% | 8.51% | 10.71% | 10.86% | 5.89% | 13.42% | 13.71% | 8.28% | 14.68% | 17.40% | 12.09% | 9.40% |
| 0.14 | 0.31 | 0.25 | 0.44 | 7.74 | 1.04 | 1.15 | 0.99 | 1.04 | 2.30 | 1.94 | 2.35 | 3.04 | |
| Interest | 0.64 | 0.53 | 0.57 | 0.39 | 0.17 | 0.08 | 0.06 | 0.09 | 0.09 | 0.25 | 0.21 | 0.34 | 0.41 |
| Depreciation | 0.92 | 0.50 | 0.56 | 0.56 | 0.32 | 0.05 | 0.03 | 0.05 | 0.12 | 0.13 | 0.26 | 0.36 | 0.42 |
| Profit before tax | 2.14 | 0.88 | 0.42 | 1.14 | 9.05 | 2.07 | 3.90 | 3.96 | 3.04 | 7.48 | 7.90 | 5.76 | 5.18 |
| Tax % | 34.11% | 34.09% | 45.24% | 59.65% | 28.07% | 29.95% | 23.59% | 25.76% | 28.62% | 25.27% | 25.82% | 26.39% | |
| 1.41 | 0.58 | 0.24 | 0.46 | 6.52 | 1.45 | 2.99 | 2.94 | 2.17 | 5.59 | 5.86 | 4.25 | 3.80 | |
| EPS in Rs | 4.44 | 1.82 | 0.76 | 1.45 | 20.51 | 4.56 | 9.41 | 9.25 | 6.83 | 17.59 | 18.44 | 13.37 | 11.96 |
| Dividend Payout % | 11.28% | 27.41% | 0.00% | 69.13% | 4.88% | 21.93% | 15.95% | 16.22% | 14.65% | 0.00% | 0.00% | 14.96% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 10% |
| 3 Years: | 8% |
| TTM: | -15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 8% |
| 3 Years: | 31% |
| TTM: | -36% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 9% |
| 3 Years: | -3% |
| 1 Year: | -54% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 16% |
| 3 Years: | 18% |
| Last Year: | 13% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 |
| Reserves | 3.33 | 3.72 | 3.96 | 4.04 | 10.56 | 11.63 | 14.23 | 16.69 | 18.36 | 23.64 | 28.76 | 32.38 | 35.93 |
| 4.44 | 5.58 | 5.01 | 3.10 | 1.41 | 0.46 | 0.00 | 0.00 | 1.31 | 4.02 | 1.95 | 4.21 | 5.34 | |
| 3.47 | 4.16 | 3.21 | 3.13 | 5.23 | 5.56 | 7.28 | 3.14 | 2.66 | 3.68 | 3.41 | 3.30 | 3.70 | |
| Total Liabilities | 14.42 | 16.64 | 15.36 | 13.45 | 20.38 | 20.83 | 24.69 | 23.01 | 25.51 | 34.52 | 37.30 | 43.07 | 48.15 |
| 5.79 | 7.62 | 7.28 | 6.78 | 0.10 | 0.20 | 0.30 | 0.67 | 0.91 | 0.86 | 2.43 | 2.49 | 2.54 | |
| CWIP | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.18 | 0.23 | 0.18 | 0.07 | 1.10 | 1.23 | 0.97 | 1.12 | 0.32 | 0.00 | 1.16 | 2.35 | 4.28 |
| 8.14 | 8.79 | 7.90 | 6.60 | 19.18 | 19.40 | 23.42 | 21.22 | 24.28 | 33.66 | 33.71 | 38.23 | 41.33 | |
| Total Assets | 14.42 | 16.64 | 15.36 | 13.45 | 20.38 | 20.83 | 24.69 | 23.01 | 25.51 | 34.52 | 37.30 | 43.07 | 48.15 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.18 | 1.56 | 1.32 | 2.42 | -10.70 | 0.43 | 0.36 | 0.22 | 7.90 | -6.50 | 6.03 | -5.83 | |
| -0.51 | -2.02 | -0.06 | 0.07 | 13.30 | 0.53 | 1.02 | 0.16 | 1.39 | 1.27 | -1.32 | 0.46 | |
| -2.88 | 0.46 | -1.28 | -2.24 | -2.26 | -1.36 | -0.87 | -0.49 | 0.79 | 2.19 | -2.88 | 1.35 | |
| Net Cash Flow | -0.21 | 0.00 | -0.01 | 0.24 | 0.33 | -0.41 | 0.50 | -0.12 | 10.08 | -3.04 | 1.83 | -4.02 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 65.71 | 74.39 | 93.22 | 89.53 | 131.65 | 94.63 | 107.41 | 99.30 | 100.34 | 77.57 | 61.43 | 44.56 |
| Inventory Days | 39.14 | 45.71 | 53.90 | 69.11 | 64.32 | 60.51 | 59.00 | 48.01 | 57.91 | 79.48 | 38.86 | 44.33 |
| Days Payable | 42.15 | 59.78 | 31.68 | 52.91 | 62.28 | 45.28 | 59.39 | 76.61 | 57.65 | 48.68 | 40.43 | 42.91 |
| Cash Conversion Cycle | 62.70 | 60.32 | 115.44 | 105.73 | 133.69 | 109.85 | 107.02 | 70.70 | 100.60 | 108.36 | 59.85 | 45.98 |
| Working Capital Days | 31.54 | 11.90 | 12.43 | 14.69 | 258.67 | 245.56 | 267.41 | 143.88 | 127.82 | 174.50 | 193.76 | 274.47 |
| ROCE % | 24.41% | 12.04% | 8.04% | 13.44% | 14.21% | 14.14% | 23.75% | 21.73% | 12.92% | 28.79% | 25.06% | 16.56% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Domestic Sales INR Lakhs |
|
||||||||||
| Export Sales INR Lakhs |
|||||||||||
| Number of Permanent Employees Number |
|||||||||||
| Debtors Turnover Ratio Times |
|||||||||||
| Annual Production Capacity (Powder or equivalent) MT |
|||||||||||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
11 Feb - Newspaper Advertisement pertaining to un-audited financial results of the Company for the quarter ended on December 31, 2025
- Financial Results For The Quarter Ended On 31.12.2025 10 Feb
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 10.02.2026
10 Feb - Approved unaudited quarterly and nine-month results for period ended 31-Dec-2025; limited review conducted by auditors.
-
Board Meeting Intimation for The Quarter Ended On 31.12.2025
2 Feb - Board meeting on 10 Feb 2026 to approve unaudited Q3 results for quarter ended 31 Dec 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
19 Jan - Certificate as per Reg 74(5) of SEBI(DP) Reg, 2018 for the quarter ended on 31.12.2025
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
VRL manufactures and exports Antacids
therapeutic category of Active Pharma Ingredients and offers products in paste, powder and micronized grade of powder. Additionally, it offers products which are used other than pharmaceutical use.